-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Benzinga·09/09/2026 17:28:49
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.